Work

Investigating the Domain Selectivity of Dual Inhibitors of Angiotensin I-Converting Enzyme and Neprilysin

Year: 2026
Type: article
Abstract: Cardiovascular diseases, driven primarily by hypertension, depend on blood pressure regulation through the renin-angiotensin-aldosterone system (RAAS), endothelin system (ES), and natriuretic peptide and kinin system (NPKS). These pathways require balanced peptide processing by enzymes such as angiotensin-converting enzyme (ACE) and neprilysin (NEP). Current antihypertensive therapies inhibit both the N-domain (nACE) and C-domain (cACE) of ACE, often causing undesirable side effects. To address this, cACE-selective inhibitors have been developed, while simultaneous inhibition of cACE and NEP has demonstrated improved pharmacological efficacy in hypertensive mice. Enzyme kinetic analyses and X-ray crystallography identified three dual cACE/NEP inhibitors (AD017, AD018, and AD019), each exhibiting approximately 10-fold selectivity for cACE over nACE. Notably, AD019 combined this cACE selectivity with low-nanomolar NEP inhibition, making it the most promising lead. These findings demonstrate that hydrophobic P1/P1′ residues and a bulky aromatic P2′ group optimally exploit the hydrophobic subsites of cACE and NEP for drug design.
Source: Biochemistry
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W7235911556
FWCI:
Cites: 36
Cited by:
Related to: 10